Is a Drug’s Launch Price a Good Indicator of Future Expenditure?

How important is it to incorporate life-cycle price modeling when conducting cost-effectiveness analyses? A newly published OHE Research Paper shows how the traditional approach to calculating ICERs could lead to the wrong decision. Read more here. (Source: OHE, 8/25/15)

You might also be interested in:

Winegarden: ICER's Cost Model 'Wrong,' 'Dangerous' 05/13/2020
PCORI’s Research Scope Expanded to Include Cost Outcomes 10/08/2020
[Webinar] Multi-Criteria Decision Analysis: Can It Help Make… 10/12/2020
The Professional Society for Health Economics and Outcomes… 08/18/2020
Lilly Partners with Prime Therapeutics: How Next Generation… 07/28/2020
US Drug Pricing Reform Post-Election 11/09/2020
HealthEconomics.Com, Scientist.Com Announce HEOR, RWE Partnership 04/10/2020